Kinex Pharmaceuticals has announced the addition of two key executives to its clinical leadership team reporting to chief medical officer, Dr. Rudolf Kwan. Douglas Kramer, M.D., joins Kinex as vice president of Clinical and Regulatory Affairs and Jane Devane has joined Kinex as director of Clinical Operations.

Kramer adds significant regulatory and clinical risk management experience and was previously a medical officer for the FDA. His experience also includes director for CNS Clinical Research at Schering-Plough where, amongst other accomplishments, he successfully led the global approval for IV Temodar, the current standard of treatment for newly diagnosed glioblastoma multiforme.

Devane spent 15 years with Schering-Plough and subsequently Merck where she worked on numerous clinical drug development projects including the global registration effort of IV Temodar.